<DOC>
	<DOCNO>NCT02095522</DOCNO>
	<brief_summary>Colchicine antiinflammatory property . It show effective improve outcome stable coronary disease . The exact mechanism unclear . Study objective : assess effect colchicine endothelial function use EndoPAT™ NSTEMI Patients . Study Hypothesis : There significant difference RH-PAT level patient treat colchicine versus placebo group Study design patient Selection One hundred forty patient diagnosis Non ST Elevation Myocardial Infarction enrol prospective randomize double-blind placebo control study Tel Aviv Medical Center , Tel Aviv , Israel . Patients recruit hospitalization cardiac catheterization . All patient sign inform consent . Primary outcome improvement endothelial function baseline 1 month group</brief_summary>
	<brief_title>COlchicine Improve EnDothElial Function Non ST Elevation Myocardial Infarction Patients</brief_title>
	<detailed_description>Study design patient Selection One hundred forty patient diagnosis Non ST Elevation Myocardial Infarction ( NSTEMI ) enrol prospective randomize double-blind placebo control study Tel Aviv Medical Center , Tel Aviv , Israel . Patients recruit hospitalization cardiac catheterization . All patient sign inform consent . Study publish NIH clinicaltrials.com database . Inclusion exclusion criterion present Table 1 Table 1 : Patient Selection Inclusion criteria 1 . NSTEMI Diagnosis 2 . Patients age 18 3 . Informed consent Exclusion criterion 1 . Hemodynamic instability 2 . Pregnant woman 3 . Peripheral vascular disease feeble absent peripheral pulse 4 . Restlessness and/or chaotic breathing 5 . Renal dialysis 6 . Severe aortic valve insufficiency/Stenosis 7 . Severe mitral valve insufficiency 8 . Congenital cardiac malformation ( structural heart disease ) 9 . Known extra-cardiac shunt 10 . Major surgery within 30 day 11 . Any medical condition would impair participation ( e.g . progressive neurological disorder , mental illness ) 12 . Known intolerance colchicine 13 . Ejection fraction le 35 % past admission CHF exacerbation last 30 day . 14 . Inflammatory diseases 15 . Current treatment steroid , NSAID , chemotherapy biologic medication Pre Study exam After enrollment , patient undergo follow baseline procedure : 1 . Physical examination medical interview 2 . Endothelial function use EndoPat® plan cardiac catheterization 3 . Blood tests- see description Blood sample An 18-gauge cannula place antecubital vein blood sample . Blood sample analysis perform use reagent , calibrators control material Bayer Diagnostics ( Berkshire , England ) ADVIA 1650 . A 40 ml blood sample obtain describe . Blood test time detailed end flow chart . Each Patient provide 40ml blood follow blood test 1 . Full chemistry include : lipid level , thyroid function , liver enzymes function , Troponin , CPK , HbA1c , uric acid , glucose level . 2 . Blood count 3 . Inflammatory biomarker ( hs-CRP , fibrinogen , IL-6 , IL-1B , IL-18 , MMP , Lp-PLA2 , procalcitonin , IL-10 , IL-35 , TNFa , AchE , , PAI-1 , MPO , cholinergic status . etc . ) 4 . Endothelial function marker : Endothelin-1 , I-CAM , V-CAM , superoxide dismutase ADMA , oxidize LDL 5 . Serum Samples store future testing . PAT score : Peripheral arterial tonometry signal obtain use EndoPAT 2000 device ( Itamar Medical Inc. , Caesarea , Israel ) , validate use previously assess peripheral arterial tone population . 14-17 Briefly , EndoPAT bio-sensors place index finger arm . EndoPAT quantifies endothelium-mediated change vascular tone , elicit 5-minute occlusion brachial artery ( use standard blood pressure cuff ) . When cuff release , surge blood flow cause endothelium-dependent Flow Mediated Dilatation ( FMD ) . The dilatation , manifest reactive hyperemia , capture EndoPAT increase PAT Signal amplitude . A post-occlusion pre-occlusion ratio calculate EndoPAT software , provide EndoPAT index . In addition , EndoPAT system measure heart rate variability .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>1 . NSTEMI Diagnosis 2 . Patients age 18 3 . Informed consent 1 . Hemodynamic instability 2 . Pregnant woman 3 . Peripheral vascular disease feeble absent peripheral pulse 4 . Restlessness and/or chaotic breathing 5 . Renal dialysis 6 . Severe aortic valve insufficiency/Stenosis 7 . Severe mitral valve insufficiency 8 . Congenital cardiac malformation ( structural heart disease ) 9 . Known extracardiac shunt 10 . Major surgery within 30 day 11 . Any medical condition would impair participation ( e.g . progressive neurological disorder , mental illness ) 12 . Known intolerance colchicine 13 . Ejection fraction le 35 % past admission CHF exacerbation last 30 day . 14 . Inflammatory diseases 15 . Current treatment steroid , NSAID , chemotherapy biologic medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>colchicine NSTEMI endothelial function inflammation</keyword>
</DOC>